Patient Advocacy and Therapeutic Development for Huntington’s Disease

July 29th, 2022|Categories: Past Webinars|

Time: 11am - 12pm EST Date: August 11, 2022 Description: Dan O'Reilly, PhD, a former OTS Trainee BoD member, focuses his research on developing siRNA therapeutics for Huntington’s Disease. Join us as Dr. O'Reilly discusses patient advocacy and Huntington’s Disease research. ...

Transitioning from Trainee to Faculty – A conversation with Prof. Bethany Powell Gray

June 30th, 2022|Categories: Past Webinars|

Time: 11am - 12pm EST Date: July 14, 2022 Description: Join us for an open discussion with Dr. Bethany Powell Gray, who is an Assisstant Professor at the John Hopkins University School of Medicine, where we will talk about the postdoc to faculty ...

Pitfalls and Progress in the Development of Immune Stimulatory Nucleic Acids

May 26th, 2022|Categories: Past Webinars|

Date: June 2, 2022 Time: 11-12 EST Speaker: Art Krieg, MD, Checkmate Pharmaceuticals Description: Art Krieg, MD, CSO at Checkmate Pharmaceuticals, focuses his research on stimulating innate immunity with immune stimulatory DNA and RNA. Join us as Dr. Krieg discusses the history of efforts ...

Antisense Oligonucleotide-based Therapies for Inherited Retinal Diseases: From Mutation to Clinical Trial

March 1st, 2022|Categories: Past Webinars|

Speaker: Alex Garanto, PhD Date: March 10, 2022 Time: 11-12 EST Description: The eye is at the forefront of therapeutic development for its unique properties. Local delivery of ASOs to the retina has shown to be well tolerated and safe. During this webinar, Prof. ...

A Perspective From Industry – A Conversation With Richard S. Geary, Ph.D. Executive Vice President, Chief Development Officer at Ionis Pharmaceuticals

February 3rd, 2022|Categories: Past Webinars|

Speaker: Richard S. Geary, Ph.D. Date: February 10, 2022 Time: 11-12 EST Description: The OTS Webinar series is pleased to feature Dr. Richard Geary, the current President Elect, and the Executive Vice President, Chief Development Officer at Ionis Pharmaceuticals. For part of the webinar ...

Go to Top